托伐普坦纠正SIADH相关低钠血症的速度预测因素
多中心历史队列研究显示,SIADH患者使用托伐普坦后24小时内血钠升高幅度与基线血钠、血清尿素氮(SUN)和eGFR相关。基线血钠和SUN是独立预测因素,低血钠(≤121 mEq/L)且低SUN(≤10 mg/dL)者血钠上升更快,需警惕过度纠正。
要点
- SIADH患者用托伐普坦后25%出现血钠日升>12 mEq/L,显著高于心衰患者的3%。
- 基线血钠和SUN是SIADH患者血钠纠正速度的独立预测因素。
- 低血钠(≤121 mEq/L)且低SUN(≤10 mg/dL)者24小时血钠平均升高15.4 mEq/L。
核心结论
- 基线血钠和SUN可预测SIADH患者使用托伐普坦后低钠血症纠正速度。
- 对低血钠且低SUN患者,托伐普坦剂量应谨慎。
研究设计与样本
- 多中心历史队列研究,纳入5家美国医院的成人SIADH或充血性心衰患者。
- 共28例SIADH和39例心衰患者,因血钠≤130 mEq/L接受托伐普坦治疗。
主要发现
- SIADH组25%出现血钠日升>12 mEq/L,心衰组仅3%(P<0.001)。
- SIADH组24小时血钠升高与基线血钠(r=-0.78,P<0.001)、SUN(r=-0.76,P<0.001)和eGFR(r=0.58,P=0.01)相关。
- 多变量分析中,基线血钠和SUN是SIADH患者血钠变化的独立预测因素。
- 低血钠(≤121 mEq/L)且低SUN(≤10 mg/dL)者24小时血钠平均升高15.4 mEq/L,显著高于其他三组(P<0.05)。
- 心衰患者中仅基线SUN是血钠变化的独立预测因素。
关键数值与推荐
- SIADH组平均基线血钠120.6 mEq/L,心衰组122.4 mEq/L。
- 过度纠正定义为血钠日升>12 mEq/L。
临床怎么用
- 对SIADH患者使用托伐普坦前应评估基线血钠和SUN。
- 低血钠(≤121 mEq/L)且低SUN(≤10 mg/dL)者需谨慎 dosing,密切监测血钠。
局限性
- 血钠系列测定和水摄入记录缺乏统一性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tolvaptan effectively corrects hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), but undesired overcorrection can occur. We hypothesized that pretherapy parameters can predict the rapidity of response to tolvaptan in SIADH. STUDY DESIGN: Multicenter historical cohort study. SETTING & PARTICIPANTS: Adults with SIADH or congestive heart failure (CHF) treated with tolvaptan for a serum sodium concentration ≤ 130 mEq/L at 5 US hospitals. PREDICTORS: Demographic and laboratory parameters. OUTCOMES: Rate of change in serum sodium concentration. MEASUREMENTS: Spearman correlations, analysis of variance, and multivariable linear mixed-effects models. RESULTS: 28 patients with SIADH and 39 patients with CHF treated with tolvaptan (mean baseline serum sodium, 120.6 and 122.4 mEq/L, respectively) were studied. Correction of serum sodium concentration > 12 mEq/L/d occurred in 25% of patients with SIADH compared to 3% of those with CHF (P<0.001). Among patients with SIADH, the increase in serum sodium over 24 hours was correlated with baseline serum sodium concentration (r=-0.78; P<0.001), serum urea nitrogen concentration (SUN; r=-0.76; P<0.001), and estimated glomerular filtration rate (r=0.58; P=0.01). Baseline serum sodium and SUN concentrations were identified as independent predictors of change in serum sodium concentration in multivariable analyses. When patients were grouped into 4 categories according to baseline serum sodium and SUN median values, those with both low baseline serum sodium (≤121 mEq/L) and low baseline SUN concentrations (≤10mg/dL) exhibited a significantly greater rate of increase in serum sodium concentration (mean 24-hour increase of 15.4 mEq/L) than the other 3 categories (P<0.05). Among patients with CHF, only baseline SUN concentration was identified as an independent predictor of change in serum sodium concentration over time. LIMITATIONS: Lack of uniformity in serial serum sodium concentration determinations and documentation of water intake. CONCLUSIONS: Baseline serum sodium and SUN values are predictive of the rapidity of hyponatremia correction following tolvaptan use in SIADH. We advise caution when dosing tolvaptan in patients with both low serum sodium and SUN concentrations.
引用
- Morris JH, Bohm NM, Nemecek BD, et al. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan. Am J Kidney Dis. 2018. PMID: 29478867. doi:10.1053/j.ajkd.2017.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。